Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives

Brain metastases are the most common central nervous system tumors in adults, and incidence of brain metastases is increasing due to both improved diagnostic techniques (e.g. magnetic resonance imaging) and increased cancer patient survival through advanced systemic treatments. Outcomes of patients remain disappointing and treatment options are limited, usually involving multimodality approaches. Brain metastases represent an unmet medical need in solid tumor care, especially in breast cancer, where brain metastases are frequent and result in impaired quality of life and death. Challenges in the management of brain metastases have been highlighted in this review. Innovative research and treatment strategies, including prevention approaches and emerging systemic treatment options for brain metastases of breast cancer, are further discussed.

• Publication year

  2018

• Venue

  Therapeutic Advances in Medical Oncology

• Publication date

  2018-06-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1758835918780312PMID 29977353PMCID 6024336
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

  2019cited by this paper
• Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

  2018cited by this paper
• Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?

  2018cited by this paper
• Repeated diffusion MRI reveals earliest time point for stratification of radiotherapy response in brain metastases

  2017cited by this paper
• Molecular characterization of breast cancer CTCs associated with brain metastasis

  2017cited by this paper
• Abstract 5008: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation

  2017cited by this paper
• Drug delivery in overcoming the blood–brain barrier: role of nasal mucosal grafting

  2017cited by this paper
• Integrating RNA sequencing into neuro‐oncology practice

  2017cited by this paper
• Genetic Characterization of Brain Metastases in the Era of Targeted Therapy

  2017cited by this paper
• The Abscopal Effect of Radiation Therapy: What Is It and How Can We Use It in Breast Cancer?

  2017cited by this paper
• Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

  2017cited by this paper
• Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases

  2017cited by this paper
• Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group.

  2017cited by this paper
• Applications of DNA-Based Liquid Biopsy for Central Nervous System Neoplasms.

  2017cited by this paper
• Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)

  2017cited by this paper
• RNAi screen identifies essential regulators of human brain metastasis-initiating cells

  2017cited by this paper
• Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.

  2017cited by this paper
• Preclinical Modeling and Therapeutic Avenues for Cancer Metastasis to the Central Nervous System

  2017cited by this paper
• Brain metastasization of breast cancer.

  2017cited by this paper
• Abstract OT1-04-08: Phase 3 study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer who have stable brain metastases previously treated with an anthracycline, a taxane, and capecitabine

  2017cited by this paper
• Final results from the dose-escalation stage of a phase 1/2 trial of TPI 287, a brain penetrable microtubule inhibitor, plus bevacizumab in patients with recurrent glioblastoma.

  2017cited by this paper
• 35P_PRAnalysis of EGFR mutation status in blood and CSF in lung adenocarcinoma patients with EGFR mutation and CNS metastasis by ddPCR

  2017cited by this paper
• Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer.

  2017cited by this paper
• TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).

  2017cited by this paper
• Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC) and brain metastases: Preliminary results from the GETUG-AFU 26 (Nivoren) study.

  2017cited by this paper
• Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.

  2017cited by this paper
• Current challenges in the management of breast cancer brain metastases.

  2017cited by this paper
• The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation

  2017cited by this paper
• Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

  2016cited by this paper
• Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier

  2016cited by this paper
• A randomized phase 2 study of nivolumab and nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases: The Anti-PD1 Brain Collaboration (ABC Study).

  2016cited by this paper
• Breast cancer brain metastases: biology and new clinical perspectives

  2016cited by this paper
• ANG1005, a novel peptide-paclitaxel conjugate crosses the BBB and shows activity in patients with recurrent CNS metastasis from breast cancer, results from a phase II clinical study

  2016cited by this paper
• The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer.

  2016cited by this paper
• Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid

  2016cited by this paper
• Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.

  2016cited by this paper
• Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

  2016cited by this paper
• Clinical trial of blood-brain barrier disruption by pulsed ultrasound

  2016cited by this paper
• Liquoral liquid biopsy in neoplastic meningitis enables molecular diagnosis and mutation tracking: a proof of concept

  2016cited by this paper
• Combination inhibition of PI3K and mTORC1 yields durable remissions in orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases

  2016cited by this paper
• Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial

  2016cited by this paper
• Stereotactic Radiotherapy combined with Immunotherapy: Augmenting Radiation’s Role in Local and Systemic Treatment

  2016cited by this paper
• Tumor-Associated CSF MicroRNAs for the Prediction and Evaluation of CNS Malignancies

  2015cited by this paper
• Response assessment criteria for brain metastases: proposal from the RANO group.

  2015cited by this paper
• Épidémiologie des lésions métastatiques cérébrales

  2015cited by this paper
• Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment.

  2015cited by this paper
• Functional diffusion map: A biomarker of brain metastases response to treatment based on magnetic resonance image analysis

  2015cited by this paper
• NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer

  2015cited by this paper
• FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies

  2015cited by this paper
• Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft

  2015cited by this paper
• A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience

  2015cited by this paper
• Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.

  2015cited by this paper
• Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.

  2015cited by this paper
• Treatment of Brain Metastases.

  2015cited by this paper
• Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

  2015cited by this paper
• Unsanctifying the sanctuary: challenges and opportunities with brain metastases.

  2015cited by this paper
• Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier.

  2015cited by this paper
• [Epidemiology of brain metastases].

  2015cited by this paper
• Role of the neural niche in brain metastatic cancer.

  2014cited by this paper
• Brain metastasis: New opportunities to tackle therapeutic resistance

  2014cited by this paper
• Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models

  2014cited by this paper
• A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity

  2014cited by this paper
• Current approaches to the treatment of metastatic brain tumours

  2014cited by this paper
• PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis

  2014cited by this paper
• The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria

  2014cited by this paper
• Treatment of Brain Metastases

  2014cited by this paper
• Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.

  2013cited by this paper
• Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline

  2013cited by this paper
• TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells

  2012cited by this paper
• Recent trends in epidemiology of brain metastases: an overview.

  2012cited by this paper
• A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors

  2012cited by this paper
• Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.

  2012cited by this paper
• Neratinib Reverses ATP-Binding Cassette B1-Mediated Chemotherapeutic Drug Resistance In Vitro, In Vivo, and Ex Vivo

  2012cited by this paper
• Intranasal administration: a potential solution for cross-BBB delivering neurotrophic factors.

  2012cited by this paper
• Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

  2012cited by this paper
• Intranasal delivery of stem cells to the brain

  2011cited by this paper
• Brain metastases as preventive and therapeutic targets

  2011cited by this paper
• Presentation, patterns of care, and survival in patients with brain metastases

  2011cited by this paper
• Inclusion of Patients with Brain Metastases in Phase I Trials: An Unmet Need

  2011cited by this paper
• Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer.

  2010cited by this paper
• Brain metastases admissions in Sweden between 1987 and 2006

  2009cited by this paper
• HER2 therapy: Molecular mechanisms of trastuzumab resistance

  2006cited by this paper
• Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.

  2004cited by this paper
• Drug and gene targeting to the brain with molecular trojan horses

  2002cited by this paper
• Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review).

  2002cited by this paper
• Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies.

  2000cited by this paper
• Inflammatory cytokines in the brain: does the CNS shape immune responses?

  1994cited by this paper

• Unveiling Novel Molecular Drivers in Breast Cancer Brain Metastasis: Multi-Omics Integration Identifies Downregulation of VCAN and Emerging Roles of ASCL2/GRAMD1A as Prognostic Biomarkers and Therapeutic Vulnerabilities

  2025cites this paper
• Altered Cell Surface N-Glycosylation Implicates Hypersialylation in Breast Cancer Brain Metastasis.

  2025cites this paper
• Two-dimensional analysis of plasma-derived extracellular vesicles to determine the HER2 status in breast cancer patients

  2025cites this paper
• New uses of halofuginone to treat cancer

  2024cites this paper
• Evaluation of the association between bevacizumab concentration and clinical outcomes in patients with breast cancer brain metastasis

  2024cites this paper
• Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases

  2023cites this paper
• Combination of ketogenic diet and probiotics inhibits breast cancer in mice by immune system modulation and reduction of Insulin growth factor-1

  2023cites this paper
• Volumetric Modulated Arc Therapy for Radiosurgery of Brain Metastases: A Single-Center Study

  2023cites this paper
• Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study

  2023cites this paper
• Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial

  2022cites this paper
• Role of ribociclib in treatment of luminal Her-2-negative mBC with CNS metastases

  2022cites this paper
• Antibody drug conjugates (ADCs): an expanding rational treatment paradigm in breast cancer

  2022cites this paper
• Role of Ultrasound Imaging in the Prediction of TRIM67 in Brain Metastases From Breast Cancer

  2022cites this paper
• CILP, a Putative Gene Associated With Immune Infiltration in Breast Cancer Brain Metastases

  2022cites this paper
• Systemic Therapy Type and Timing Effects on Radiation Necrosis Risk in HER2+ Breast Cancer Brain Metastases Patients Treated With Stereotactic Radiosurgery

  2022cites this paper
• Hirnmetastasen und Meningeosis neoplastica

  2022cites this paper
• Breast Cancer Subtypes and Mortality of Breast Cancer Patients With Brain Metastasis at Diagnosis: A Population-Based Study

  2021cites this paper
• A Substantial Response from Adding Palbociclib to Endocrine Therapy in Brain Metastasis from Hormone Receptor-Positive, HER2-Negative Breast Cancer: Case Reports

  2021cites this paper
• CILP Inhibits Brain Metastasis by Meditating Mast Cells via the MAPK Signaling Pathway in Breast Cancer

  2021cites this paper
• Mechanical tibial loading remotely suppresses brain tumors by dopamine-mediated downregulation of CCN4

  2021cites this paper
• Gene expression profiles of breast cancer metastasis according to organ site

  2021cites this paper
• Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis

  2021cites this paper
• Development of next-generation tumor-homing induced neural stem cells to enhance treatment of metastatic cancers

  2021cites this paper
• Volumetric modulated arc radiosurgery for brain metastases from breast cancer: A single-center study

  2021cites this paper
• Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood–brain barrier disruption: where are we now, and where we are going

  2020cites this paper
• Downregulation of circulating miR 802‐5p and miR 194‐5p and upregulation of brain MEF2C along breast cancer brain metastasization

  2020cites this paper
• The management of elderly patients with brain metastases from breast cancer

  2020cites this paper
• Blocking c-MET/ERBB1 Axis Prevents Brain Metastasis in ERBB2+ Breast Cancer

  2020cites this paper
• A view on the landscape of breast cancer brain metastases

  2020cites this paper
• Development of CNS metastases in breast cancer patients treated with curative intent: a case–control study

  2020cites this paper
• Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis

  2020cites this paper
• Heterogeneity and vascular permeability of breast cancer brain metastases.

  2020cites this paper
• Systemic Therapy of Brain Metastases: Breast Cancer

  2020cites this paper
• The Emerging Role of Adhesion GPCRs in Cancer.

  2020cites this paper
• Circulating MicroRNAs and Blood-Brain-Barrier Function in Breast Cancer Metastasis

  2020cites this paper
• Synergistic chemotherapy for breast cancer and breast cancer brain metastases via paclitaxel-loaded oleanolic acid nanoparticles.

  2020cites this paper
• Brain metastatic breast cancer: Epidemiology, survival and prognosis: Single center experience

  2020cites this paper
• Case series review of neuroradiologic changes associated with immune checkpoint inhibitor therapy.

  2020cites this paper
• Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells

  2020cites this paper
• Rab11b-mediated integrin recycling promotes brain metastatic adaptation and outgrowth

  2019cites this paper
• MiR-182-5p Knockdown Targeting PTEN Inhibits Cell Proliferation and Invasion of Breast Cancer Cells

  2019cites this paper
• Is active targeting of brain metastases of breast cancer superior to passive targeting?

  2019cites this paper
• Tackling the challenges of brain metastases in solid tumors.

  2018cites this paper